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Abstract — Aims: The aims were to provide proofs of mechanism and principle by establishing the ability of the amino acid
L-tryptophan (Trp) combined with the kynureninase inhibitor benserazide (BSZ) to inhibit the liver mitochondrial low Km aldehyde
dehydrogenase (ALDH) activity after administration and in vivo and to induce aversion to alcohol. Methods: Trp, BSZ or both were
administered to male Wistar rats and ALDH activity was determined both in vitro in liver homogenates and in vivo (by measuring
acetaldehyde accumulation in blood after ethanol administration). Alcohol consumption was studied in an aversion model in rats and
in alcohol-preferring C57 mice. Results: Combined administration of Trp+BSZ, but neither compound alone, produced a strong
inhibition of ALDH activity and an increase in blood acetaldehyde concentration after ethanol, and induced aversion to alcohol in
rats and decreased preference in mice. Another kynureninase inhibitor, carbidopa, induced aversion to alcohol by itself, which was
reversed by Trp co-administration. Conclusions: The present results establish a prior art for the use of a combination of Trp plus
BSZ in the treatment of alcoholism by aversion, which merits rapid clinical development.
INTRODUCTION
In the preceding paper (Badawy et al., 2011), we have
demonstrated the ability of 3 tryptophan (Trp) metabolites of
the kynurenine pathway, namely 3-hydroxykynurenine
(3-HK), 3-hydroxyanthranilic acid (3-HAA) and kynurenic
acid (KA), to inhibit the rat liver mitochondrial low Km alde-
hyde dehydrogenase (ALDH) activity after administration, to
elevate blood acetaldehyde concentration following acute
ethanol administration and to induce aversion to alcohol in
an experimental rat model. On the basis of these findings,
we suggested that the above metabolites may form the basis
of a new alcohol aversion therapy. A US patent (to AA-BB)
is expected shortly for the use of 3-HK and 3-HAA and suit-
able derivatives thereof in the treatment of alcoholism by
aversion. However, the clinical development of these metab-
olites and their derivatives requires further studies. A more
immediate and potentially superior alternative approach is to
use their parent compound Trp. However, Trp acutely admi-
nistered alone may not produce sufficient sustainable
ALDH-inhibitory amounts of the above kynurenine metab-
olites, but can do so if given under suitable conditions,
namely metabolic blockade at the kynureninase step of the
hepatic kynurenine pathway. As well as via this major
pathway of Trp degradation, Trp is also metabolized by three
minor pathways, the serotonin-biosynthetic, the decarboxyla-
tion or tryptamine and the transamination, pathways (Fig. 1)
(for reviews, see Badawy, 2002, 2005). It is important to
emphasize here a number of aspects of the kynurenine
pathway (for review, see Bender, 1982) in the context of the
present work, namely that: (a) the most rate-limiting enzyme
is Trp 2,3-dioxygenase, with the next rate-limiting enzyme
being kynureninase and that kynurenine hydroxylase is not
rate-limiting under normal conditions. (b) Kynurenine ami-
notransferase catalyses minor reactions under normal con-
ditions, but these could become quantitatively more
significant under conditions of loading with Trp or kynure-
nine (Bender, 1982). (c) The main kynureninase reaction in
the liver is that using 3-HK and not kynurenine as substrate
(Bender, 1982) (although in the in vitro assays of this
enzyme, kynurenine is usually used). (d) Blockade of the
kynureninase reaction will inhibit the formation of 3-HAA,
which, in turn, will limit quinolinic acid formation. (e)
Kynureninase blockade in the presence of Trp loading could
also lead to accumulation of KA. (f) This latter metabolite is
the physiological antagonist, whereas quinolinic acid is the
physiological agonist, of the N-methyl-D-aspartate (NMDA)
type of glutamate receptors (Stone, 1993) and, although
entry of KA into the brain is normally relatively limited, that
of kynurenine is not (Fukui et al., 1991). Quinolinic acid
entry into the brain has also been suggested to be equally
limited (Fukui et al., 1991), although other evidence suggests
that peripheral blood plays a significant role in its cerebral
uptake (Heyes and Morrison, 1997). It is therefore possible
that Trp loading combined with liver kynureninase inhibition
could afford dual neuronal protection against NMDA recep-
tor activity. (g) With Trp loading, formation of serotonin in
the brain is also expected to be enhanced.
As progress in developing more effective drug therapies is
hampered by the multifactorial nature of the alcohol depen-
dence process and the limited capacity of current and potential
drugs to influence only one aspect of this process, it has been
suggested (Mann, 2004; Johnson, 2008) that progress is more
likely to be achieved using combination therapy. Our pro-
posed strategy, based on the above principles, appears to
satisfy the requirements for a potentially successful alcoholism
therapy, one acting simultaneously on alcohol consumption
through aversion, on anxiety and depression, and possibly
also reward, through provision of serotonin and on hyperexcit-
ability through decreased NMDA receptor function.
In the present paper, we provide evidence for proof of
mechanism (ALDH inhibition) and of principle (induction of
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with the kynureninase inhibitor benserazide (BSZ). This
latter drug is best known for its inhibition of aromatic
L-amino acid decarboxylase (ALAAD) activity during
therapy of Parkinson’s disease when co-administered with
the dopamine precursor 3,4-dihydroxyphenylalanine
(L-dopa). The other ALAAD inhibitor carbidopa (also used
with L-dopa) is an even-stronger kynureninase inhibitor
(Bender and Smith, 1978; Bender, 1980) and was therefore
also studied in the present work.
MATERIALS AND METHODS
Chemicals and other materials
BSZ [DL-serine 2(2,3,4-trihydroxybenzyl) hydrazine hydro-
chloride] and carbidopa [2(S)-3-(3,4-dihydroxyphenyl)-
2-hydrazino-2-methylpropanoic acid] were purchased from
the Sigma-Aldrich Co Ltd. (Fancy Road, Poole, Dorset,
UK). All other chemicals and materials were purchased from
this and the other sources listed in the preceding paper
(Badawy et al., 2011).
Animals and treatments
Adult normal male Wistar rats weighing between 150 and
170 g at the start of experiments were purchased from accre-
dited animal suppliers and were acclimatized to our standard
UK Home Office-approved housing conditions (21 ±2°C,
relative humidity of 55±10% and a 12 h/12 h light:dark
cycle) for at least one week before experiments. They were
housed five per cage, unless stated otherwise, in convention-
al open-top cages with standard softwood bedding from
accredited suppliers, and were allowed free access to stan-
dard laboratory RM1 diet and water. Adult male mice of the
Fig. 1. Schematic representation of the tryptophan degradative pathways. These are: 1. the kynurenine pathway; 2. the serotonin pathway; 3. the
decarboxylation or tryptamine pathway; 4. the aminotransferase pathway. Metabolites in bold letters are inhibitors of ALDH activity.
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and 21 g at the start of experiments, were also studied. This
study was performed under the auspices of Cardiff
University and approved and licensed (project licence No:
PPL 30/2502) by the UK Home Office under the Animal
(Scientific Procedures) Act 1986. All compounds were admi-
nistered intraperitoneally in 0.9% (w/v) NaCl (physiological
saline) in single doses as follows: Trp (50 mg/kg); BSZ
(100 mg/kg), carbidopa (50 mg/kg). When administered in
combinations, BSZ, carbidopa or an equal volume (1 ml/kg)
of saline was injected 15 min, 30 min or 1 h before Trp or an
equal volume of saline ((2.5 ml/kg). When given repeatedly
for up to 7 days, BSZ, carbidopa and Trp were injected in
single daily doses either separately or in combinations as
above.
Determination of ALDH activity in vitro and in vivo
The mitochondrial low Km ALDH activity was determined
in vitro by the method of Tottmar et al. (1973) in liver super-
natants prepared according to Mazzanti et al. (1989), and in
vivo by measuring the accumulation of acetaldehyde in
blood following acute ethanol administration. Both pro-
cedures have been described in detail in the preceding paper
(Badawy et al., 2011). The blood acetaldehyde concen-
trations reported in the ‘Results’ section in the present paper
have also been corrected for the artifactual formation
described in the preceding paper, in which pitfalls in acet-
aldehyde determination have been addressed in detail.
Alcohol aversion test
Aversion to alcohol was assessed using the alcohol aversion
model of Garver et al. (2000). Briefly, individually housed
rats were allowed free access to food and water for 3 days.
Trp, BSZ or carbidopa were administered in the above single
doses once daily for 4 days, either separately or in combi-
nations wherein BSZ, carbidopa or saline was injected 15
min before Trp or saline. On the evening of the third day,
water (but not food) was withdrawn for 18 h, but was then
replaced by a 6% (v/v) ethanol solution, 2 h after the injec-
tion on the fourth day. Body wt was measured daily and
alcohol consumption was monitored hourly for 4 h and
levels were expressed cumulatively over this duration in g/kg
body wt.
Alcohol consumption and preference in alcohol-preferring
C57BL/6J mice
As in the preceding paper (Badawy et al., 2011), no attempt
was made to enhance alcohol preference by acclimatizing the
mice to increasing ethanol concentrations, as the purpose of
our study was to investigate aversion, rather than preference.
Accordingly, four groups (n=8 each) of individually housed
mice were given free choice between drinking water and a
10% (v/v) ethanol solution for 16 days to establish their
drinking patterns. Thereafter, mice were pretreated once daily
with a single intraperitoneal injection of BSZ (100 mg/kg
body wt) or an equal volume (1 ml/kg) of saline 0.25 h
before a similar injection of Trp (50 mg/kg) or an equal
volume (2.5 ml/kg) of saline, for 5 days. Body wt and water
and ethanol consumption were recorded daily throughout the
whole study duration. Determined per kg body wt, daily
alcohol consumption was expressed in absolute amounts (g)
and as a percentage of total fluid intake (% preference).
Determination of liver kynureninase activity
Liver kynureninase activity was determined by measuring
the conversion of kynurenine to anthranilic acid by the
method of Chiarugi et al. (1995). In preliminary experiments,
we found that kynureninase activity was linear over the
kynurenine concentration range of 0–1 mM and that anthra-
nilic acid formation from kynurenine (1 mM) was linear over
a 90 min period. Subsequent experiments were therefore per-
formed at a 1 mM kynurenine concentration with a 30 min
incubation time. A 1 g piece of frozen liver was homogen-
ized in 4 ml of an ice-cold homogenization buffer consisting
of 20 mM sodium phosphate, containing 140 mM KCl at pH
7.0 for 1 min using an ultra-Turrax homogenizer. The hom-
ogenate was then centrifuged at 20 000g for 30 min at 4°C.
The supernatant was then decanted quantitatively and the
volume adjusted to 4 ml with the homogenization buffer. All
tests were performed in duplicates with one blank for each
rat liver homogenate. To 100 µl of the ice-cold substrate sol-
ution (200 mM Tris–HCl buffer, pH 8.0, 100 µM pyridoxal
50-phosphate and 1 mM kynurenine), 100 µl of the rat liver
homogenate was added in a 5 ml plastic tube. The mixture
was incubated in a shaking-water bath for 30 min at 37°C.
The reaction was stopped by the addition of 200 µl of 24%
(w/v) perchloric acid and incubation was continued for a
further 2–3 min. The contents of the tubes were centrifuged
at 10 000g for 10 min at 4°C, after which the supernatant
was decanted carefully into an high-performance liquid-chro-
matographic (HPLC) autosampler vial. The anthranilic acid
produced was separated and quantified both fluorimetrically
and by UV as described below for kynurenine metabolites.
The protein content of the liver postmitochondrial super-
natant was determined by the method of Lowry et al. (1951)
using bovine albumin as standard. Enzyme activity was
expressed as nmol of anthranilic acid formed/h per mg of
protein.
Assessment of kynureninase activity in vivo
This can be made by measuring hepatic concentrations of
some kynurenine metabolites. The major effect of kynureni-
nase inhibition is elevation of 3-HK concentration (Chiarugi
et al., 1995), leading to a decrease in that of 3-HAA. A sec-
ondary effect is a potential increase in xanthurenic acid due
to elevation of [3-HK]. Hepatic concentrations of the above
three and other metabolites were therefore determined in the
present experiments, using the HPLC methodology of
Badawy and Morgan (2010) under the conditions described
in the preceding paper (Badawy et al., 2011).
Statistical analysis
Enzymatic and other biochemical test results were compared
with those of control groups by the unpaired t test, whereas
alcohol consumption results were assessed initially by
one-way analysis of variance (ANOVA) and additionally for
within-group differences (time factor versus baseline values)
by paired t-tests, using Sigma Plot (Systat, UK), version 11,
with which graphics were prepared. For multiple group com-
parisons using this programme, the Holm-Sidak test was
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tests and can be used for both pairwise comparisons and
those versus a control group. Where the data failed the nor-
mality (Shapiro–Wilk) test, Kruskal–Wallis one-way
ANOVA on ranks was performed. A two-tailed level of
significance (P) was set at 0.05.
RESULTS
Effects of administration of BSZ or carbidopa alone or in
combinations with tryptophan on the rat liver mitochondrial
low Km ALDH activity
The acute effects are depicted in Fig. 2. Neither BSZ alone
(Fig. 2a) nor carbidopa alone (Fig. 2b) exerted any signifi-
cant effects on ALDH activity. Similarly, Trp administered
alone or with carbidopa did not influence ALDH activity
(Fig. 2b). By contrast, combined administration of Trp plus
BSZ caused a remarkable inhibition (Fig. 2a). Thus, ALDH
activity was decreased by this combined treatment by 46% at
1h( P= 0.0005). Inhibition then progressed over time, reach-
ing 92% at 3 h and remaining at this level 1 h later.
Chronic experiments were also performed in which rats
were treated with Trp, BSZ or a combination of the two for
7 days. In data not shown, neither Trp alone nor BSZ alone
exerted any significant effect on ALDH activity, whereas the
combined treatment caused a 55% inhibition (P =0.0001)
Although this could be attributed to an acute effect at 2 h
after the final treatment, it suggests that no tolerance devel-
ops to the acute inhibition after repeated administration of
Trp plus BSZ.
Inhibition of AlDH activity in vivo by combined
administration of tryptophan and BSZ
The accumulation of acetaldehyde and ethanol in blood fol-
lowing acute ethanol administration was studied in rats
treated with Trp, BSZ or a combination of the two (Fig. 3).
Blood acetaldehyde concentration (Fig. 3a) after pretreatment
with BSZ did not differ significantly from that in saline-
pretreated controls (P >0.0980). A non-significant trend
towards elevated acetaldehyde concentration after pretreat-
ment with Trp was observed (P>0.0971). By contrast, com-
bined pretreatment with Trp plus BSZ caused a significant
elevation of blood acetaldehyde concentration. The strongest
effect was at 1 h after ethanol (145 μM), which was signifi-
cantly different from all the other three groups (P =0.0287–
0.0001). At 2 h, the increase caused by Trp plus BSZ was
also significant, compared with those in saline or
BSZ-pretreated rats (P= 0.0029), but, at 3 h, only the differ-
ence from saline-pretreated controls was still significant (P =
0.0011). Acetaldehyde concentration in Trp plus
BSZ-pretreated rats did not differ significantly from that in
Trp-pretreated rats at 2 or 3 h.
The increase in blood ethanol concentration following
ethanol administration to saline-pretreated controls was not
significantly influenced by pretreatment with BSZ, Trp or
both (Fig. 3b). Pretreatment with Trp alone showed a slightly
lower blood ethanol concentrations at 3 h, though not signifi-
cant (P>0.1). The ethanol area under the curve (AUC) was
similar among the saline-, BSZ- and Trp plus BSZ-pretreated
groups (80.35, 80.95 and 81.85 mM, respectively) and
slightly higher than that in the Trp-pretreated group (76.9
mM).
Demonstration of aversion to alcohol after administration of
tryptophan in combination with BSZ, but not with carbidopa
In the preceding paper (Badawy et al., 2011), we have suc-
cessfully applied the alcohol aversion model of Garver et al.
(2000) to demonstrate aversion to alcohol by three kynure-
nine metabolites and to confirm that by the classical AlDH
inhibitor disulfiram. In the present work, we tested the same
model for possible aversion by Trp and the two kynureninase
inhibitors BSZ and carbidopa either alone or in combination
with Trp. As the results in Fig. 4 show, no aversion to
alcohol was observed after administration of Trp alone. BSZ
alone (Fig. 4a) also did not inhibit alcohol consumption,
except only at 2 h. This particular effect appears to be a spur-
ious result, as it did not occur earlier nor was it maintained
thereafter, and it does not fit in with other results described
Fig. 2. Time-course of effects of acute administration of tryptophan, BSZ,
carbidopa and combinations of tryptophan with BSZ or carbidopa on
activity of the rat liver mitochondrial low km ALDH. Tryptophan (50 mg/
kg), BSZ (100 mg/kg) or carbidopa (50 mg/kg) was administered
intraperitoneally to rats. BSZ (a) or carbidopa (b) was also administered 30
min before tryptophan (all in the above doses). ALDH activity was
determined before and at hourly intervals for 4 h after these treatments as
described in the ‘Materials and Methods’ section. Values are means±SEM
(bars) for each group of five rats. Values at the different time-intervals were
compared statistically (t-test) with those at zero time and the significance of
the differences is indicated by an asterisk (P<0.0005). Abbreviations used:
BSZ, benserazide; CBD, carbidopa; Trp, tryptophan.
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alcohol, decreasing alcohol consumption by 30–33% consist-
ently at 2–4h ( P= 0.0162–0.0017), in comparison with
saline-treated controls.
Combined administration of Trp with carbidopa (Fig. 4b),
however, reversed the carbidopa-induced aversion. Here,
alcohol consumption resembled that of saline-treated con-
trols. By contrast, combined treatment with Trp plus BSZ
(Fig. 4a) induced consistent inhibition of alcohol consump-
tion, of 38–44% at 1–4h ( P= 0.0127–0.0024), compared
with saline-treated controls. Alcohol consumption with this
combined treatment also differed significantly from that with
the Trp-treated group at all four time-intervals (P =0.0253–
0.0030) and from the BSZ-treated group at 1 and 4 h
(P =0.0274–0.0106).
Effects of tryptophan, BSZ or both on alcohol consumption
and preference by C57 mice
After a 16-day period of provision of free choice between
drinking water and a 10% (v/v) ethanol solution, four groups
(n=8 each) of male alcohol-preferring C57BL/6J mice were
treated with single daily doses of saline, Trp, BSZ or a com-
bination of Trp plus BSZ. Six mice from each group were
matched on Day 0 for level of alcohol consumption (in g/kg
body wt) and preference (%) adjusted per kg body wt, as
shown in Fig. 5. There were no significant differences on
any one day between the groups receiving saline, Trp or
BSZ, either in absolute ethanol intake (Fig. 5a) or preference
(Fig. 5b) (ANOVA’s, P >0.1). By contrast, combined admin-
istration of Trp+BSZ led to lower levels of alcohol con-
sumption and preference. Alcohol intake (g/kg) in this
combined group differed significantly only on Day 5 from
that in the BSZ- and Trp-treated groups (P =0.05–0.034),
whereas alcohol preference (%) differed significantly from
that in the saline group on Days 1and 3 (P =0.039–0.015),
the Trp group on Days 1, 3 and 5 (P =0.044–0.003) and the
Fig. 4. Inhibition of alcohol consumption by carbidopa alone and by
combined treatment with BSZ and tryptophan in a rat alcohol aversion
model. Groups of rats received single daily intraperitoneal injections for 4
days of BSZ (100 mg/kg body wt), carbidopa (50 mg/kg) or an equal
volume (1 ml/kg) of saline 1 h before a similar injection of tryptophan (50
mg/kg) or an equal volume (2.5 ml/kg) of saline. All other details are as
described in the ‘Materials and Methods’ section. Consumption of the
ethanol solution was measured hourly in all groups for 4 h and is expressed
in g/kg body wt cumulatively. Values are means±SEM (bars) for each
group of 5–6 rats. Sal (saline) and other abbreviations are as in Fig. 2.
Fig. 3. Effects of acute administration of BSZ, tryptophan or both on rat
blood ethanol and acetaldehyde concentrations. Rats received an
intraperitoneal injection of BSZ (100 mg/kg body wt) or an equal volume
(1 ml/kg) of saline 1 h before a similar injection of tryptophan (50 mg/kg) or
an equal volume (2.5 ml/kg) of saline. One hour after the second injection, a
2 g/kg dose of ethanol (as a 25% v/v solution in saline) was administered.
Blood samples were analysed for acetaldehyde (a) and ethanol (b)a s
described in the ‘Materials and Methods’ section. Values are means±SEM
(bars) for each group of five rats. All test groups were compared with the
saline-pretreated control group (C) by the t-test. The BSZ plus tryptophan
group was additionally compared with the other two test groups as described
in the relevant text of the ‘Results’ section. Abbreviations used are as in
Fig. 2a.
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data and the graphs, it is clear that, whereas the three single
groups exhibited a cyclical alcohol consummatory behaviour,
with a high and a lower intake on alternate days, the com-
bined Trp+ BSZ group consistently decreased its alcohol
intake continuously with time. Accordingly, because of this
cyclical behaviour of the single treatment groups, the
absence of significant differences between the Trp+BSZ
group and the other three was apparent only on days on
which mice of these latter groups decreased their alcohol
intake.
Inhibition of liver kynureninase activity by BSZ and
carbidopa and the differential effect of combined treatment
with tryptophan
The two most potent inhibitors of kynureninase activity in
vitro are carbidopa and BSZ, with the former being a stron-
ger inhibitor (Bender and Smith, 1978; Bender, 1980). This
was partially confirmed in the present work. As shown in
Table 1, kynureninase inhibition was similar between BSZ
and carbidopa at drug concentrations of 10 μM (17–22%),
25 μM (25–28%) and 100 μM (32–33%). However, at larger
concentrations, the inhibition by carbidopa was almost twice
as strong (61 vs 36% at 250 μM and 80 vs 44% at 500 μM).
Kynurenine aminotransferase activity was also determined
simultaneously with that of kynureninase by measuring the
increase in KA formation. In data to be reported elsewhere,
both BSZ and carbidopa inhibited kynurenine aminotransfer-
ase activity, with the inhibition by carbidopa being stronger
than that by BSZ at all concentrations tested.
Kynureninase activity was also determined after the acute
administration of BSZ, carbidopa, Trp and combinations of
Trp with either drug. The results in Fig. 6a show that Trp
alone did not inhibit kynureninase activity. Trp adminis-
tration (30 mg/kg intraperitoneally) has previously been
reported (Takeuchi and Shibata, 1984) to enhance kynureni-
nase activity by 15 and 21% at 2 and 3 h, respectively. As
no such enhancement was observed in the present work at
these time-intervals, a closer examination of a possible early
increase was made. At 1.5 h after Trp administration, kynure-
ninase activity (6.08 ±0.49, expressed as in Fig. 5) was still
not significantly different (P> 0.1) from the control zero-
time value (5.78 ±0.27). However, a significant increase of
37% was observed at 0.5 h (7.91 ± 0.26; P =0.0005).
As expected, both BSZ and carbidopa inhibited kynureni-
nase activity. As shown in Fig. 6b, BSZ caused a significant
inhibition (43%; P= 0.0003) only at 1 h, whereas carbidopa
(Fig. 6c) caused a similar inhibition (41%; P =0.0013) at 2
h. The inhibition by BSZ was not undermined by combined
Trp administration (Fig. 6b). In fact, a constant level of inhi-
bition (of 30–35%; P= 0.0196–0.0036) was sustained over
the first 3 h, and that at 4 h (23%) was still significant (P =
0.0462). As BSZ was administered 30 min before Trp, the
latter could be said to have prolonged the BSZ inhibition by
3.5 h. By contrast, the kynureninase inhibition by carbidopa
was totally reversed by co-administration of Trp (Fig. 6c).
Kynureninase activity was also determined after chronic
administration of Trp, BSZ or both for 7 days. In data not
shown, kynureninase activity was decreased by BSZ by 22%
and co-administration of Trp did not modify this decrease. In
fact, Trp induced a further decrease. Trp alone exerted no
effect on kynureninase activity. Under these chronic con-
ditions, BSZ also inhibited kynurenine aminotransferase
Fig. 5. Effects of repeated administration of BSZ, tryptophan or both on
alcohol consumption and preference in male alcohol-preferring C57BL/6J
mice. Experimental details are as described in the ‘Materials and Methods’
section. Alcohol consumption was monitored daily and is expressed (per kg
body wt) for each group from day zero (before the injections) onwards, both
in g amounts (a) and as a preference % (b). Values are means±SEM (bars)
for each group of six mice. For abbreviations, see Fig. 4. For statistical
comparisons, see the relevant text in the ‘Results’ section.
Table 1. Inhibition of liver kynureninase activity in vitro by BSZ and
carbidopa
Kynureninase activity (nmol of
anthranilic acid formed/h per mg
of protein)







Enzyme activity was determined as described in the ‘Materials and
Methods’ section. Values are means±SEM for each group of liver
preparations from four rats. The asterisk denotes a significant difference
from the corresponding control value (P=0.0450–0.0000).
666 Badawy et al.activity, by 61% and Trp, which exerted no significant effect
when given alone, caused a further significant decrease when
co-administered with BSZ (data not shown).
Hepatic kynurenine metabolites after the acute
administration of tryptophan, carbidopa, BSZ or various
combinations
As stated above, the main effect of kynureninase inhibition
(by BSZ and carbidopa) is the elevation of hepatic [3-HK].
However, because these two drugs also inhibit kynurenine
aminotransferase activity, the potential increase in xanthure-
nic acid (due to 3-HK elevation) may be hampered by such
latter inhibition. Although hepatic concentrations of Trp and
six of its kynurenine metabolites were measured in the
present work, only the data on [3-HK] are reported here, as
details of other changes and their discussion fall outside the
scope of this paper. As shown in Fig. 7, the 3-HK precursor
Trp administered alone caused relatively large increases in
liver [3-HK] at 3–4 h, with the 190% increase at 3 h being
significant, compared with the zero-time control value (P =
0.016). The much smaller increases at 1 and 2 h were not
significant. By contrast and as expected, both BSZ (Fig. 7a)
and carbidopa (Fig. 7b) induced large increases in [3-HK]
(P =0.004–0.001), which were comparable at 1 and 2 h.
Fig. 6. Time-course of effects of acute administration of tryptophan, BSZ,
carbidopa or a combination of tryptophan with BSZ or carbidopa on rat liver
kynureninase activity. Experimental details are as described for the ALDH
experiments in Fig. 2. Kynureninase activity was determined as described in
the ‘Materials and Methods’ section. Values are means±SEM (bars) for
each group of five rats for tryptophan alone (a), BSZ with and without
tryptophan (b) and carbidopa with and without tryptophan (c). For
abbreviations, see Fig. 4.
Fig. 7. Time-course of increases in hepatic 3-HK concentration after acute
administration of tryptophan, BSZ, carbidopa or a combination of
tryptophan with BSZ or carbidopa. 3-HK concentration was determined in
livers of the same rats undergoing the time-course experiments with ALDH
and kynureninase reported in Figs. 2 and 6 as described in the ‘Materials
and Methods’ section. Values are means±SEM (bars) for each group of five
rats for the BSZ (a) and carbidopa (b) experiments. Abbreviations and
comparisons are as in Figs. 2, 4 and 6.
Tryptophan, benserazide and alcoholism treatment 667Thereafter, the [3-HK] elevations by carbidopa remained
close to the maximum increases, whereas those by BSZ
showed a dramatic drop towards normal values.
When BSZ administration was followed 0.5 h later by that
of Trp, a dramatic elevation of [3-HK] was observed at 1 h
after the Trp injection, with a 1069% increase over the base-
line zero-time value (P =0.008). This increase was a 152%
higher than that induced by BSZ alone at this time-interval
(P = 0.008). The [3-HK] elevation by the combined BSZ
plus Trp treatment continued to be much higher than that by
BSZ alone at the 2–4 h time points (P =0.05–0.001). By
contrast, when carbidopa was administered 0.5 h before Trp,
there was no potentiation of the carbidopa-induced elevation
of [3-HK] by Trp. In fact, none of the [3-HK] values
observed with this combination differed significantly from
those obtained with carbidopa alone at 1–3h( P>0.1) and
the value at 4 h was even 26% smaller (P =0.034) after the
combined treatment.
Animal body weights during repeated administration
of tryptophan, BSZ or both
In the aversion experiments reported in Fig. 4, rats gained
weight during the first 3 days of the test. However, as was
the case with disulfiram and kynurenine metabolites in the
preceding paper (Badawy et al., 2011), a wt loss of 6–7%
occurred in all group rats on the morning of the fourth day,
following the 18 h-water-deprivation period.
Changes in body wt of rats given single daily injections of
saline, Trp, BSZ or a combination of Trp plus BSZ for 7
days in the chronic experiments were also recorded. Rats of
all groups gained wt. On Day 7, the wt gain over the starting
wt on Day 1 was 19, 21, 21 and 17%, respectively for the
above four groups. No significant differences in body wt
were observed after analysis of variance in within- or
between-group comparisons (P >0.1).
Body weights of mice in the preference experiments were
also recorded. All mice (n=32) gained wt during the 16-day
free choice period (from 19.44±0.16 to 21.85± 0.21 g; P <
0.001) (means± SEM). Body weights remained stable during
the 6-day drug administration period, with small rises of 1–
3%. No significant differences within- or between-groups
were observed (P >0.1). Both rats and mice appeared
healthy and showed no adverse reactions or unusual
behaviours.
DISCUSSION
Inhibition of ALDH activity by combined administration
of tryptophan plus BSZ
The present study was based on the assumption that Trp
administered alone is metabolized along the kynurenine
pathway so rapidly that sufficient levels of its
ALDH-inhibitory metabolite 3-HK (Badawy et al., 2011)
may not be achieved or sustained to any significant extent,
but that this could occur after metabolic blockade of the
further degradation of 3-HK to 3-HAA by inhibition of
kynureninase activity (Fig. 1). This assumption was borne
out by the present findings that the combined administration
of Trp plus the kynureninase inhibitor BSZ (but not Trp
alone) caused a strong and sustained inhibition of the rat
liver mitochondrial low Km ALDH activity (Fig. 2a). This is
almost certainly due to this combination inducing a remark-
able and sustained elevation of hepatic [3-HK] (Fig. 7a)
resulting from kynureninase inhibition by BSZ [shown here
under acute (Fig. 6b) and chronic (see the text) conditions as
well as in vitro (Table 1)] superimposed on supply of 3-HK
by its Trp precursor. As shown in Fig. 7, Trp alone increased
liver [3-HK] significantly only at 3 h, but to a much lesser
extent than that observed after kynureninase inhibition by
BSZ. The latter drug alone did not influence the mitochon-
drial low Km enzyme after acute (Fig. 2a) or chronic (see the
text) administration. As carbidopa also inhibits kynureninase
activity (Bender and Smith, 1978; Bender, 1980), it was also
studied in the present work. Surprisingly, carbidopa did not
inhibit ALDH activity after acute administration either alone
or in combination with Trp (Fig. 2b), although it inhibited
kynureninase activity both in vitro (Table 1) and after acute
administration (Fig. 6c) and induced increases in liver
[3-HK] (Fig. 7b) comparable with those by BSZ alone
(Fig. 7a). Furthermore, Trp did not potentiate the increase in
liver [3-HK] caused by carbidopa (Fig. 7b) and this may
explain the failure of the combined Trp plus carbidopa treat-
ment to inhibit ALDH activity. As ALDH activity was not
inhibited by Trp, BSZ, carbidopa or the latter combined with
Trp, it may be suggested that the [3-HK] elevation under
these four conditions (up to ~50 μM) (Fig. 7) was not suffi-
cient to cause inhibition of the enzyme when assayed in
vitro. In the ALDH assay in vitro, the liver is diluted a
100-fold and the resulting [3-HK] of up to 0.5 μM under the
above conditions may have been too small to cause inhi-
bition, whereas a 3-HK concentration of >1 μM in the com-
bined Trp plus BSZ group was more effective. ALDH
activity has previously been shown to be inhibited by
chronic administration of BSZ (Messiha, 1977) and acute
administration of carbidopa (Messiha, 1978a). However, this
author used the cytosolic, rather than the mitochondrial low
Km, enzyme in both studies.
The kynureninase inhibition by BSZ was prolonged by
Trp after acute administration (Fig. 6b) and potentiated after
chronic administration (see the text). A possible explanation
of these effects of Trp is the greater elevation of [3-HK] after
the combined treatment, compared with that after BSZ alone.
Evidence from kinetic studies with purified recombinant
human kynureninase demonstrating a sigmoidal
concentration-activity profile suggests that 3-HK may inhibit
kynureninase activity at higher concentrations (Walsh and
Botting, 2002). By contrast, Trp prevented the kynureninase
inhibition by carbidopa (Fig. 6c). It is well known (Vilter,
1964) that many hydrazine compounds inactivate pyridoxal
50-phosphate-dependent enzymes by forming inactive hydra-
zides with this cofactor. As both BSZ and carbidopa possess
a hydrazine group, the above differential effect of Trp on
kynureninase inhibition by BSZ and carbidopa is intriguing
and requires further investigation. Trp itself stimulated
kynureninase activity transiently at 0.5 h, by 37% (Fig. 6a).
A15–21% stimulation has previously been observed by
Takeuchi and Shibata (1984) at 2–3 h after a 30 mg/kg body
wt dose of Trp. The latter authors did not provide a possible
explanation of this stimulation in normal rats (as opposed to
an inhibition they reported in vitamin B6-deficient animals
due to depletion of the pyridoxal 50-phosphate cofactor
through the flux of Trp down the kynurenine pathway). It is
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carbidopa to undermine its effect on this enzyme, but further
work is required to elucidate the nature of such a potential
interaction.
Inhibition of ALDH activity in vivo by combined
administration of tryptophan plus BSZ
The above ALDH inhibition by combined administration of
Trp plus BSZ was also observed in vivo, as the results in
Fig. 3 show. This combined treatment induced a large
increase in blood acetaldehyde concentration following acute
ethanol administration (Fig. 3a), which mirrored the [3-HK]
elevation (Fig. 7a). Whereas BSZ alone exerted no effect on
blood acetaldehyde, Trp showed a trend towards elevation,
though the increases were not significant. The data in
Fig. 3b show Trp to cause small, though not significant,
decreases in blood-ethanol concentration at 2 and 3 h. It is
possible that significant decreases could occur at subsequent
time intervals after Trp administration, possibly due to accel-
eration of ethanol oxidation through provision of NAD
+.A s
this redox cofactor is a terminal metabolite of the kynurenine
pathway (Fig. 1), its concentration could be expected to
show a greater rise at later time-intervals.
Induction of aversion to alcohol by combined administration
of tryptophan plus BSZ
The combined treatment of rats with Trp plus BSZ induced a
decrease in alcohol consumption in the aversion model of
Garver et al. (2000) (Fig. 4a), consistent with the ALDH
inhibition observed after their combined administration and
in the in vivo assay, whereas neither compound caused aver-
sion when administered separately. The effect of Trp on
alcohol consumption is a controversial one, with an increase
(Myers and Melchior, 1975) and a decrease (Sprince et al.,
1972) having both been reported following Trp adminis-
tration in the rats’ diet. BSZ has also previously been shown
not to inhibit alcohol consumption by cats (Baskina and
Lapin, 1982)o rr a t s( Messiha, 1978b; Miñano and Myers,
1989) after systemic (intraperitoneal or subcutaneous) admin-
istration, but, when given intracerebroventricularly to rats
whose alcohol consumption was augmented by prior cyana-
mide treatment, it decreased it (Miñano and Myers, 1989).
While this experimental paradigm may have scientific merit
for the purposes of this particular study, it is clearly an artifi-
cial one not applicable to standard human pharmacotherapeu-
tic practice. By contrast, carbidopa has been reported to
inhibit alcohol consumption (Messiha, 1978b). Our finding
(Fig. 4b) that this kynureninase inhibitor induced aversion to
alcohol by itself supports this previous finding. An unex-
pected finding in the present work was the ability of Trp to
block the alcohol aversive effect of carbidopa (Fig. 4b). The
mechanism of the carbidopa-induced aversion to alcohol
cannot be explained at present. Messiha (1978b) suggested
ALDH inhibition as a possible mechanism, though as stated
above, this inhibition was demonstrated (Messiha, 1978a)
using the cytosolic enzyme. An effect of carbidopa on blood
acetaldehyde after ethanol administration, however, cannot
be ruled out. However, in the absence of such evidence and
in view of the failure of carbidopa to inhibit the mitochon-
drial low Km enzyme (Fig. 2b), other mechanisms must be
considered, including central ones. As Trp also prevented the
kynureninase inhibition by carbidopa (Fig. 6c), it is possible
that this latter effect may be related to the above effects on
alcohol consumption. However, a more likely, or additional,
explanation for the modulation by Trp of the carbidopa
effect on alcohol consumption may be related to carbidopa
metabolism. Unlike BSZ, which is metabolised and distribu-
ted almost entirely outside the brain (Schwartz et al., 1974),
carbidopa is metabolised in rats first by deamination to
α-methyldopa, which can readily cross the blood-brain
barrier to form α-methyl dopamine, and this is then followed
by β-hydroxylation to α-methyl noradrenaline (Shelton et al.,
1985). These latter authors suggested that the main function
of α-methyl dopamine formed centrally through carbidopa
metabolism is via α-methyl noradrenaline, which is a potent
α2 adrenoceptor agonist, which may influence alcohol con-
sumption. Thus, one α2-agonist, lofexidine, has been
reported (Lê et al., 2005) to attenuate stress-induced rein-
statement of alcohol-seeking behaviour and to also decrease
alcohol self-administration, whereas the opposite effects were
induced by the α2 antagonist yohimbine. Another α2 agonist,
FLA-57, also reduces alcohol consumption (Socaransky
et al., 1985; Daoust et al., 1990). The brain entry of
α-methyldopa formed peripherally from carbidopa could be
inhibited through competition by Trp, which shares the same
carrier mechanism responsible for the transport of neutral
(aromatic and branched-chain) amino acids and also L-dopa
itself across the blood-brain barrier (Oldendorf, 1971). For
example, administration of L-dopa (200 mg/kg) to rats
decreases brain [Trp] and [5-HT] (Algeri and Cerletti, 1974),
and it is believed that the incidence of depressive symptoms
in patients with Parkinson’s disease is due to serotonin
depletion secondarily to exogenous L-dopa inhibiting Trp
uptake by the brain, with Trp administration successfully
alleviating these symptoms (Miller and Nieberg, 1974). A
larger L-dopa dose (500 mg/kg), however, elevates brain
[Trp] by increasing plasma [free Trp] secondarily to stimulat-
ing the lipolytic release of non-esterified fatty acids (Curzon,
1974). It is therefore possible that aversion to alcohol
induced by carbidopa may involve a central mechanism and
that Trp blocks it by preventing the cerebral uptake of the
carbidopa metabolite α-methyldopa. Further work will be
required to assess this possibility.
The combined tryptophan-BSZ strategy for alcoholism
treatment
The above results have provided proofs of mechanism
(ALDH inhibition after administration and in vivo) and prin-
ciple (induction of aversion to alcohol) by the combined
administration of Trp and the kynureninase inhibitor BSZ. A
European patent (to AA-BB) is expected shortly for use of
this combination in alcoholism treatment by aversion and
proof of concept studies demonstrating the ability of this
combination to induce aversion to alcohol in human subjects
will be an important step in the further development of this
intellectual property. This proposed combination is not
limited to its aversive property, but can address several other
aspects of the alcohol dependence mechanism in addition to
alcohol consumption. Thus: (1) the use of Trp can elevate
brain serotonin levels to counteract two important determi-
nants of relapse after detoxification, namely anxiety and
depression. (2) A third determinant of relapse is the
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believed to be due to NMDA receptor activation (Gonzales,
1990; Lovinger, 1995) and suggested to be mediated by the
endogenous NMDA receptor agonist quinolinic acid
(Morgan, 1991). Minimizing the peripheral formation of this
Trp metabolite by kynureninase inhibition (Fig. 1) can only
contribute to its decreased entry into the brain (Heyes and
Morrison, 1997). (3) Furthermore, cerebral levels of the
NMDA receptor antagonist KA are likely to be increased
through increased entry of kynurenine into the brain with
Trp loading. Thus, plasma and brain kynurenine concen-
trations have been shown (Gál et al., 1978) to be increased at
1h after intraperitoneal administration of a 50 mg/kg body wt
dose of Trp by 110 and 57% respectively. In the present
work, serum Trp and kynurenine concentrations after chronic
administration of Trp in the above single daily dose for 7
days were increased by 121 and 131% respectively and joint
BSZ administration influenced the kynurenine elevation only
moderately (data not shown). Although Trp competes with
kynurenine for cerebral uptake (see Møller, 1985 and refer-
ences cited therein), the above proportionate increases are
unlikely to cause an imbalance in entry of either compound
into the brain. Although BSZ inhibits liver kynurenine ami-
notransferase activity (data not shown), a similar effect in the
brain is unlikely as BSZ does not cross the blood-brain
barrier. Accordingly, the combined Trp plus BSZ treatment
is likely to lead to elevation of cerebral KA concentration,
leading to NMDA receptor antagonism. The proposed com-
bination could therefore afford dual neuronal protection. (4)
As regards reward mechanisms, although the above negative
reinforcing properties (anxiety, depression and hyperexcit-
ability) appear to play a more important role in alcohol
dependence than the positive rewarding effects, it is also
possible that provision of serotonin from Trp in the proposed
therapy may modulate the alcohol reward effect. Although
dopamine plays a central role in the brain reward mechan-
isms, other neurotransmitters are also capable of modulating
this role, including serotonin, GABA (γ-aminobutyric acid),
glutamate and endogenous opioids (Koob and Nestler, 1997)
and the importance of the interactions between these systems
has been emphasized in relation to alcohol research and treat-
ment (Lê et al., 1996). It is therefore possible that
Trp-derived serotonin could also modulate alcohol reward
through interacting with dopaminergic and opioidergic, and
possibly other, systems. We therefore believe that the
Trp-BSZ combination represents a new and unique multifa-
ceted approach to combination therapy of alcohol
dependence.
There should be little safety issues with the combined use
of Trp plus BSZ. In the present work (see the text), test rats
and mice gained weight at a normal rate as control animals
and showed no side effects. Weight gain and food intake
were also reported to be normal after repeated subcutaneous
BSZ administration (Miñano and Myers, 1989). Both Trp
and BSZ are currently licensed for use in resistant
depression and Parkinson’s disease, respectively (the latter in
combination with L-dopa). A clinical trial for treatment of
schizophrenia with Trp plus BSZ for 6 weeks did not report
undue adverse events different from those experienced by a
control schizophrenic group treated with chlorpromazine
(Chouinard et al., 1978). The combined use of Trp plus BSZ
is also the subject of a US patent (United States Patent,
1993) for the treatment of chronic pain, in which the inventor
successfully used this combination in humans with no
reported adverse events. BSZ alone has also been used in a
trial in schizophrenia (Chouinard et al., 1977) with no
reported adverse events.
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